Longer PPPM length of hospital stay (3.0 vs. 1.2 days) and more frequent outpatient visits (1.7 vs. 1.4 times) in anaplastic lymphoma kinase (ALK) inhibitor-treated NSCLC patients with BM compared to those without BM were also observed in a previous study [19]. Here, ALK is linked to non-small cell lung carcinoma.